Southampton’s Curve Therapeutics closes £40.5m funding round
Curve Therapeutics has raised more than £40.5 million in a Series A funding round led by Pfizer Ventures.
The Southampton Science Park-based biotech secured investment from Columbus Venture Partners and British Patient Capital. They join founding investor Advent Life Sciences and seed round co-lead Epidarex Capital.
Dr Simon Kerry, CEO of Curve Therapeutics, said: “This financing will enable us to expand our team, progress our lead assets into the clinic and to expand our Microcycle drug discovery platform.
“We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth.”
Read the March 2024 issue of The Business Magazine, including our feature on skills
CSO Professor Ali Tavassoli added: “Curve’s Microcycle platform is a powerful tool for drug discovery, enabling an unparalleled advantage in the discovery of functional hits and leads.
“We look forward to maximising the potential of our platform to further develop a rich pipeline of programmes with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer.”
In basing its operations in Hampshire, Curve enjoys proximity to four universities, as well as pioneering medical institutions like the Centre for Cancer Immunology in Southampton.
Dr Marie-Claire Peakman, partner at Pfizer Ventures, added: “We’re delighted to have led this financing and to work with great co-investors and leadership team.
“Curve’s platform provides an exciting new approach designed to tackle tough, high-priority targets which have been difficult to progress in the past.”
Read more - Southampton Science Park puts out call for Catalyst business accelerator
